Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism

European Journal of Endocrinology

Volumn 153, Issue 4, 2005, Pages 587-594

  Kawata, Takehisa ^a,b   Imanishi, Yasuo ^a   Kobayashi, Keisuke ^a   Kenko, Takao ^a   Wada, Michihito ^b   Ishimura, Eiji ^a   Miki, Takami ^a   Nagano, Nobuo ^b   Inaba, Masaaki ^a   Arnold, Andrew ^c   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KIRIN BREWERY CO LTD   (Japan)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM ION; CALCIUM SENSING RECEPTOR; CINACALCET; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; HORMONE INHIBITION; HYPERCALCEMIA; IN VIVO STUDY; MOUSE; NONHUMAN; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RODENT; SINGLE DRUG DOSE;

AGING; ANIMALS; CALCIUM; GENES, BCL-1; HYPERPARATHYROIDISM; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; NAPHTHALENES; PARATHYROID GLANDS; PARATHYROID HORMONE; RECEPTORS, CALCIUM-SENSING;

EID: 27644594407     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02007     Document Type: Article

References (32)

1. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM & Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991 350 512-515.
2. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL & Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997 276 404-407.
3. Imanishi Y & Tahara H. Putative parathyroid tumor suppressor on 1p: independent molecular mechanisms of tumorigenesis from 11q allelic loss. American Journal of Kidney Disease 2001 38 S165-S167.
4. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS & Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1766-1770.
5. Hosokawa Y, Pollak MR, Brown EM & Arnold A. Mutational analysis of the extracellular Ca(2 + )-sensing receptor gene in human parathyroid tumors. Journal of Clinical Endocrinology and Metabolism 1995 80 3107-3110.
6. Cetani F, Pinchera A, Pardi E, Cianferotti L, Vignali E, Picone A, Miccoli P, Viacava P & Marcocci C. No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. Journal of Bone Mineral Research 1999 14 878-882.
7. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1996 81 1598-1606.
8. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E & Drueke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney International 1997 51 328-336.
9. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J &Hebert SC. Cloning and characterization of an extracellular Ca(2 + )-sensing receptor from bovine parathyroid. Nature 1993 366 575-580.
10. Brown EM & MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiological Reviews 2001 81 239-297.
11. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG & Seidman CE. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nature Genetics 1995 11 389-394.
12. Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R & Arnold A. Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. Journal of Clinical Investigation 2001 107 1093-1102.
13. Bilezikian JP, Potts JT Jr, Fuleihan Gel H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R & Wells SA. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism 2002 87 5353-5361.
14. Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O'Fallon W & Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. Journal of Bone Mineral Research 1999 14 1700-1707.
15. Rossini M, Gatti D, Isaia G, Sartori L, Braga V & Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. Journal of Bone Mineral Research 2001 16 113-119.
16. Selby PL & Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. New England Journal of Medicine 1986 314 1481-1485.
17. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, Del Mar EG & Balandrin MF. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. PNAS 1998 95 4040-4045.
18. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D & Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. Journal of Pharmacology and Experimental Therapeutics 2004 308 627-635.
19. Antonsen JE, Sherrard DJ & Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney International 1998 53 223-227.
20. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W & Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney International 2000 58 436-445.
21. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM & Coburn JW. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology 2002 13 1017-1024.
22. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA & Bushinsky DA. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. Journal of the American Society of Nephrology 2003 14 575-583.
23. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB & Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. New England Journal of Medicine 2004 350 1516-1525.
24. Silverberg SJ, Bone HG 3rd, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL & Bilezikian JP. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. New England Journal of Medicine 1997 337 1506-1510.
25. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD & Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 5644-5649.
26. Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK & Wada M. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrology Dialysis Transplantation 2001 16 1870-1878.
27. Imanishi Y, Koyama H, Inaba M, Okuno S, Nishizawa Y, Morii H & Otani S. Phosphorus intake regulates intestinal function and polyamine metabolism in uremia. Kidney International 1996 49 499-505.
28. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H & Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. Journal of Clinical Investigation 1997 100 2977-2983.
29. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF & Fox J. Calcimimetic NPSR-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney International 2000 57 50-58.
30. Wada M & Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrology Dialysis Transplantation 2003 18 (Suppl 3) iii13-iii17.
31. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Molecular Pharmacology 1998 53 1083-1088.
32. 2+ receptor /metabotropic glutamate chimeric receptors. Endocrinology 2000 141 4156-4163.